194 related articles for article (PubMed ID: 29773230)
21. A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases.
Sato JO; Sallum AM; Ferriani VP; Marini R; Sacchetti SB; Okuda EM; Carvalho JF; Pereira RM; Len CA; Terreri MT; Lotufo SA; Romanelli PR; Ramos VC; Hilario MO; Silva CA; Corrente JE; Saad-Magalhães C;
Clin Exp Rheumatol; 2009; 27(6):1031-8. PubMed ID: 20149327
[TBL] [Abstract][Full Text] [Related]
22. Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis.
Kishi T; Warren-Hicks W; Bayat N; Targoff IN; Huber AM; Ward MM; Rider LG;
Rheumatology (Oxford); 2021 May; 60(5):2134-2145. PubMed ID: 33067611
[TBL] [Abstract][Full Text] [Related]
23. Juvenile dermatomyositis with Anti-SAE antibodies in a Moroccan child associated with pseudo-angioedema: a case report.
Nainia K; Aouzal MA; Ouafik I; Charhbili M; Bouchhab A; Daoudi A; Tizki S; Chakiri R
Pediatr Rheumatol Online J; 2024 May; 22(1):57. PubMed ID: 38773611
[TBL] [Abstract][Full Text] [Related]
24. [Juvenile dermatomyositis and new autoantibodies: Cases and review].
Guarella M; Jurquet AL; Retornaz K; Bardin N; Chastang MC; Desjonquere M; Fabien N; Belot A
Arch Pediatr; 2015 Dec; 22(12):1263-7. PubMed ID: 26598044
[TBL] [Abstract][Full Text] [Related]
25. Juvenile dermatomyositis associated with autoantibodies to small ubiquitin-like modifier activating enzyme: a report of 4 cases from North India and a review of literature.
Vignesh P; Barman P; Basu S; Mondal S; Ishran B; Kumrah R; Dod A; Garg R; Rawat A; Singh S
Immunol Res; 2023 Feb; 71(1):112-120. PubMed ID: 36278969
[TBL] [Abstract][Full Text] [Related]
26. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children.
Wang X; Ding Y; Zhou Z; Hou J; Xu Y; Li J
Pediatr Rheumatol Online J; 2021 Jan; 19(1):6. PubMed ID: 33407621
[TBL] [Abstract][Full Text] [Related]
28. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies.
Rider LG; Shah M; Mamyrova G; Huber AM; Rice MM; Targoff IN; Miller FW;
Medicine (Baltimore); 2013 Jul; 92(4):223-243. PubMed ID: 23877355
[TBL] [Abstract][Full Text] [Related]
29. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis.
Fisler RE; Liang MG; Fuhlbrigge RC; Yalcindag A; Sundel RP
J Am Acad Dermatol; 2002 Oct; 47(4):505-11. PubMed ID: 12271292
[TBL] [Abstract][Full Text] [Related]
30. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment.
Kim S; El-Hallak M; Dedeoglu F; Zurakowski D; Fuhlbrigge RC; Sundel RP
Arthritis Rheum; 2009 Jun; 60(6):1825-1830. PubMed ID: 19479872
[TBL] [Abstract][Full Text] [Related]
31. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis.
Kasteler JS; Callen JP
J Am Acad Dermatol; 1997 Jan; 36(1):67-71. PubMed ID: 8996263
[TBL] [Abstract][Full Text] [Related]
32. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety.
Al-Mayouf SM; Laxer RM; Schneider R; Silverman ED; Feldman BM
J Rheumatol; 2000 Oct; 27(10):2498-503. PubMed ID: 11036850
[TBL] [Abstract][Full Text] [Related]
33. The arthritis of inflammatory childhood myositis syndromes.
Tse S; Lubelsky S; Gordon M; Al Mayouf SM; Babyn PS; Laxer RM; Silverman ED; Schneider R; Feldman BM
J Rheumatol; 2001 Jan; 28(1):192-7. PubMed ID: 11196524
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.
Gil B; Merav L; Pnina L; Chagai G
Clin Rheumatol; 2016 Aug; 35(8):2125-2130. PubMed ID: 25846833
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of intravenous Ig therapy in juvenile dermatomyositis.
Lam CG; Manlhiot C; Pullenayegum EM; Feldman BM
Ann Rheum Dis; 2011 Dec; 70(12):2089-94. PubMed ID: 21978999
[TBL] [Abstract][Full Text] [Related]
36. Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population.
Manwatkar A; Padiyar S; Nair A; Jha A; Kumar S; Yadav B; Prakash JAJ; Das JK; Mathew J
Clin Rheumatol; 2023 Dec; 42(12):3289-3297. PubMed ID: 37801141
[TBL] [Abstract][Full Text] [Related]
37. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial.
Godeau B; Chevret S; Varet B; Lefrère F; Zini JM; Bassompierre F; Chèze S; Legouffe E; Hulin C; Grange MJ; Fain O; Bierling P;
Lancet; 2002 Jan; 359(9300):23-9. PubMed ID: 11809183
[TBL] [Abstract][Full Text] [Related]
38. Autoantibodies in children with juvenile dermatomyositis: A single centre experience from North-West India.
Hussain A; Rawat A; Jindal AK; Gupta A; Singh S
Rheumatol Int; 2017 May; 37(5):807-812. PubMed ID: 28331982
[TBL] [Abstract][Full Text] [Related]
39. Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis.
Guseinova D; Consolaro A; Trail L; Ferrari C; Pistorio A; Ruperto N; Buoncompagni A; Pilkington C; Maillard S; Oliveira SK; Sztajnbok F; Cuttica R; Corona F; Katsicas MM; Russo R; Ferriani V; Burgos-Vargas R; Solis-Vallejo E; Bandeira M; Baca V; Saad-Magalhaes C; Silva CA; Barcellona R; Breda L; Cimaz R; Gallizzi R; Garozzo R; Martino S; Meini A; Stabile A; Martini A; Ravelli A
Clin Exp Rheumatol; 2011; 29(1):117-24. PubMed ID: 21345298
[TBL] [Abstract][Full Text] [Related]
40. [Juvenile dermatomyositis-what's new?].
Hinze C
Z Rheumatol; 2019 Sep; 78(7):627-635. PubMed ID: 31087132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
